SI1385514T1 - Spiroindenske in spiroindanske spojine - Google Patents

Spiroindenske in spiroindanske spojine

Info

Publication number
SI1385514T1
SI1385514T1 SI200230789T SI200230789T SI1385514T1 SI 1385514 T1 SI1385514 T1 SI 1385514T1 SI 200230789 T SI200230789 T SI 200230789T SI 200230789 T SI200230789 T SI 200230789T SI 1385514 T1 SI1385514 T1 SI 1385514T1
Authority
SI
Slovenia
Prior art keywords
spiroindene
spiroindane compounds
spiroindane
compounds
compound
Prior art date
Application number
SI200230789T
Other languages
English (en)
Slovenian (sl)
Inventor
Richard R Goehring
Donald Kyle
Samuel Victory
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SI1385514T1 publication Critical patent/SI1385514T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200230789T 2001-04-18 2002-04-18 Spiroindenske in spiroindanske spojine SI1385514T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28467001P 2001-04-18 2001-04-18
PCT/US2002/012357 WO2002085354A1 (en) 2001-04-18 2002-04-18 Spiroindene and spiroindane compounds
EP02725733A EP1385514B9 (en) 2001-04-18 2002-04-18 Spiroindene and spiroindane compounds

Publications (1)

Publication Number Publication Date
SI1385514T1 true SI1385514T1 (sl) 2009-04-30

Family

ID=23091075

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230789T SI1385514T1 (sl) 2001-04-18 2002-04-18 Spiroindenske in spiroindanske spojine

Country Status (13)

Country Link
US (1) US6828440B2 (enExample)
EP (2) EP1385514B9 (enExample)
JP (1) JP4489354B2 (enExample)
AT (1) ATE413175T1 (enExample)
AU (1) AU2002256282C1 (enExample)
CA (1) CA2443938C (enExample)
CY (1) CY1108731T1 (enExample)
DE (1) DE60229736D1 (enExample)
DK (1) DK1385514T5 (enExample)
ES (1) ES2316559T3 (enExample)
PT (1) PT1385514E (enExample)
SI (1) SI1385514T1 (enExample)
WO (1) WO2002085354A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
PT1491212E (pt) 2002-03-29 2012-11-16 Mitsubishi Tanabe Pharma Corp Medicamento para distúrbios de sono
MXPA05010724A (es) 2003-04-04 2005-12-15 Merck & Co Inc Derivados de las espiropiperidinas aciladas como agonistas del receptor de la melanocortina-4.
GB0328906D0 (en) * 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CA2563164A1 (en) 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) * 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
MX2007002033A (es) * 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
JP2008521825A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
JP2009507800A (ja) 2005-09-09 2009-02-26 ユーロ−セルティーク エス．エイ． 縮合およびスピロ環化合物ならびにその使用
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
AU2006330866A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
RU2008137583A (ru) * 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейшн (Us) Спиропиперидины в качестве модуляторов мускариновых рецепторов
CN101426499A (zh) 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
EP2040706A2 (en) * 2006-06-29 2009-04-01 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007284350A1 (en) * 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
TWI448289B (zh) 2007-08-31 2014-08-11 Purdue Pharma Lp 經取代之喹啉型哌啶化合物及其用途
EP2207549A1 (en) * 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
US8383629B2 (en) * 2008-02-27 2013-02-26 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
UA99540C2 (ru) 2008-07-21 2012-08-27 Пердью Фарма Л.П. Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
US8431700B2 (en) * 2009-03-03 2013-04-30 Vanderbilt University Alkylsulfonyl-2,3-dihydrospiro[indene-1,4′-piperidine] analogs as GlyT1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
PE20190403A1 (es) 2016-07-29 2019-03-13 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1335831A (fr) 1962-10-09 1963-08-23 Res Lab Dr C Janssen Nv Procédé de préparation de nu-(3, 3-diphényl-3-alcanoyl)-propylspiro
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3325499A (en) 1964-11-02 1967-06-13 Mcneilab Inc 1-(1-hydrocarbyl-4-piperdyl)-2-indolinone
US3666764A (en) * 1970-08-26 1972-05-30 Mead Johnson & Co Spiroindenylpiperidines
DE2609645A1 (de) 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US4410528A (en) 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
JPS58180481A (ja) 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
EP0445974A3 (en) * 1990-03-05 1992-04-29 Merck Sharp & Dohme Ltd. Spirocyclic antipsychotic agents
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
AU693087B2 (en) * 1993-01-28 1998-06-25 Merck & Co., Inc. Spiro-substituted azacycles as tachykinin receptor antagonists
US5457207A (en) 1993-10-05 1995-10-10 Regents Of The University Of Minnesota Spirovesamicols
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AU688498B2 (en) 1994-04-14 1998-03-12 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
FR2722190B1 (fr) 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
DE69621469T2 (de) 1995-09-13 2002-12-12 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidin-derivate
WO1997040035A1 (en) 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
AU732329B2 (en) 1997-05-30 2001-04-12 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivative
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
EP0921125B1 (en) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
DK1049689T3 (da) 1998-01-19 2002-07-22 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
WO1999048492A1 (en) 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
EP1080091A1 (en) 1998-05-18 2001-03-07 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
JP2001011050A (ja) 1999-04-30 2001-01-16 Sankyo Co Ltd 含窒素飽和複素環化合物
WO2001022919A2 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
NZ524681A (en) 2000-09-06 2005-09-30 Ortho Mcneil Pharm Inc A method for treating allergies using substituted pyrazoles
AU2001288110A1 (en) * 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds

Also Published As

Publication number Publication date
WO2002085354A1 (en) 2002-10-31
CA2443938A1 (en) 2002-10-31
AU2002256282B2 (en) 2005-08-11
EP1385514B1 (en) 2008-11-05
EP2033644A1 (en) 2009-03-11
US20030018041A1 (en) 2003-01-23
ATE413175T1 (de) 2008-11-15
DK1385514T5 (da) 2009-03-09
EP1385514B9 (en) 2009-08-12
JP4489354B2 (ja) 2010-06-23
CA2443938C (en) 2010-06-22
AU2002256282C1 (en) 2006-08-17
DK1385514T3 (da) 2009-01-19
CY1108731T1 (el) 2014-04-09
JP2004532223A (ja) 2004-10-21
US6828440B2 (en) 2004-12-07
EP1385514A4 (en) 2005-04-13
EP1385514A1 (en) 2004-02-04
DE60229736D1 (de) 2008-12-18
PT1385514E (pt) 2009-02-04
ES2316559T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
SI1385514T1 (sl) Spiroindenske in spiroindanske spojine
ZA200307239B (en) 7,9-substituted tetracycline compounds.
SI1975164T1 (sl) Oktahidrobenzimidazolonske spojine kot analgetiki
UA74439C2 (uk) Сполуки спіропіразолу
SG77195A1 (en) Fungicidal 2-methoxybenzophenones
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
NO20024766D0 (no) Etyldiaminderivater
YU82303A (sh) Analozi nociceptina
WO2003041664A1 (fr) Cosmetiques contenant un mineral argileux
WO2002085291A3 (en) Nociceptin analogs
IL154014A0 (en) Process for the preparation of 2-aminoethylpyridines
MXPA04004937A (es) Proceso para preparar 3,3??,3,6??,-tetraalquil-2,2??-bifenoles y 3,??,6,??-tetraalquil-5,??-dihalo-2,??-bifenoles.
EP1186616A4 (en) ANTIFUCOIDAN ANTIBODY
EP1557407A4 (en) NEW ALPHA-CETOAMIDE DERIVATIVE AND USE THEREOF
DE60237360D1 (en) Glycopeptidantibiotika
DE60322856D1 (enExample)